Clinical trials: Familial Primary Pulmonary Hypertension
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
StratosPHere (Non-interventional Study)
Pulmonary Arterial Hypertension is a progressive disease that has no cure. Patients die young and are limited in their daily activity. Current treatments only treat the symptoms of the disease rather than the underlying cause.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Hypertension, Respiratory Disease
- Trial name
- NCT05767918
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Papworth Hospital NHS Foundation Trust
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06072417
- Testing
- Assessment without intervention at High altitude, Relocation to sea level for 2 days
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.
The purpose of this study is to determine if patients with pulmonary hypertension and mildly elevated heart pressure known as PCWP will exhibit different patterns on echocardiography and that these patterns will predict treatment…
- Trial name
- LV strain (NCT01800292)
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Artery Hypertension, Chronic Hepatitis c
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
The purpose of this study is the evaluation of PAH in patients, who are treated with DAA medication for HCV infection.
- Trial name
- NCT04094272
- Testing
- transthoracic doppler-echocardiography (TTE)
- Where
- Switzerland
- Volunteers
- 49 people
- Sponsor
- Kantonsspital Olten
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Pulmonary Artery Hypertension
Non-Invasive Measurements of Changes in Pulmonary Artery Pressure in Intensive Care Unit Patients Using Electrical Impedance Tomography - A Feasibility Study
To assess whether changes in electrical impedance - measured using an electrical impedance tomography (EIT) chest belt - can be used to derive changes in pulmonary artery pressure (PAP) in critically ill patients when compared to…
- Trial name
- PAP-EIT (NCT06544148)
- Testing
- Electrical impedance tomography
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pulmonary Hypertension
The Role of Endothelin in Pulmonary Hypertension
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
- Trial name
- NCT00759408
- Testing
- BQ-123
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Healthy Volunteer
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers.
- Trial name
- NCT05567367
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI), Vardenafil Oral Tablet
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Respira Therapeutics, Inc.
Idiopathic Pulmonary Arterial Hypertension
Empagliflozin in Pulmonary Arterial Hypertension
The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial…
- Trial name
- Emphower PoC (NCT05493371)
- Testing
- Empagliflozin 10 MG
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Amsterdam UMC, location VUmc
Scleroderma, Pulmonary Artery Hypertension
Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure).
- Trial name
- CALIPSO (NCT04610788)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Johns Hopkins University
Pulmonary Artery Hypertension, Congenital Heart Disease
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires
Background: A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers.
- Conditions
- Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
- Trial name
- NCT03152773
- Testing
- MRI Heart guidewire catheterization
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Hypertension
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
This study aims to compare the effectiveness and safety of two treatment approaches for patients with severe pulmonary hypertension: standard targeted drug therapy alone, and a combination of standard targeted drugs plus Qishen…
- Trial name
- NCT07604805
- Testing
- Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension, Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Provincial People's Hospital
Hypertension, Pulmonary
Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients
Pulmonary arterial hypertension (PAH) involves the narrowing of blood vessels connected to and within the lungs. Focal adhesion kinase (FAK) is a focal adhesion-associated protein kinase involved in cellular adhesion and…
- Trial name
- NCT02551653
- Testing
- [11C]-GSK2256098 500 MBq
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Artery Hypertension
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension
- Trial name
- NCT06035861
- Testing
- XBD173
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Hypertension
Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the endothelin receptor antagonist…
- Trial name
- NCT00120380
- Testing
- Aerosolized iloprost
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Hannover Medical School
Idiopathic Pulmonary Arterial Hypertension
Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension
Recent researches indicate that impairment of vascular and endothelial homeostasis plays a major role in the initiation and development of IPAH.We have recently reported the safety and feasibility data for autologous endothelial…
- Trial name
- NCT00641836
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Zhejiang University
Pulmonary Hypertension
Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics
The objective of this clinical research is to analyze the survival of a cohort of patients newly diagnosed (incident cases) with idiopathic PAH, familial or associated with the use of anorectics (isolated pulmonary vascular…
- Trial name
- EFORT (NCT01185730)
- Testing
- Right Heart Catheterization
- Where
- France
- Volunteers
- 165 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension, Ayerza Syndrome
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).
- Conditions
- Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
- Trial name
- NCT00086463
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Actelion
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center